Summary: In a randomised trial in men with type 2 diabetes, 12 weeks of combined aerobic and resistance training improved modelled first- and second-phase insulin secretion and glucose effectiveness more than either exercise type alone or no exercise.
PICO Summary
| Element | Detail |
|---|---|
| Population | 45 men with type 2 diabetes (mean age 55, HbA1c 7.1%, duration 12.5 years); 12-week RCT, Iran. |
| Intervention | Combined training: aerobic (25–45 min at 70–75% max HR, 3×/week) plus resistance (2×/week). |
| Comparison | Aerobic alone, resistance alone, or no-exercise control (each n=11–12). |
| Outcome | Combined training gave the largest gains: first-phase insulin secretion +53.4%, second-phase +38.9%, glucose effectiveness +12.8% (all p≤0.001), exceeding both single-modality groups. Aerobic and resistance training each improved secretion less. Baseline beta-cell function, fat-mass reduction, and glycaemic improvement predicted first-phase gains. |
Exercise type and beta-cell function in type 2 diabetes
RCT · type 2 diabetes · 12 weeks
Combined aerobic plus resistance training improved modelled first- and second-phase insulin secretion and glucose effectiveness more than aerobic or resistance training alone, with the largest first-phase gain (+53.4%). Surrogate model-based endpoints, 45 men, 12 weeks only.
Expert Commentary
This is a mechanistically ambitious trial that goes beyond HbA1c to interrogate beta-cell function, the defect that ultimately drives disease progression, and that focus is its main appeal. The signal is coherent and arguably synergistic, since the combined-training gain in first-phase secretion exceeded the simple sum of aerobic and resistance effects, fitting the complementary logic of aerobic exercise improving insulin sensitivity while resistance training expands muscle as a glucose sink. The finding that better-preserved baseline beta-cell function predicted larger gains is clinically resonant, supporting earlier intervention before exhaustion sets in. I would interpret the impressive percentages with care, however: the secretion measures are derived from validated models rather than gold-standard clamp testing, the sample is small at 45 across four arms, the trial enrolled only men with relatively well-controlled diabetes, and twelve weeks cannot speak to durability. Can I use this with my patients? Yes, and it sharpens existing advice. It reinforces prescribing combined aerobic and resistance training rather than either alone, ideally early in the disease, framed not merely as calorie-burning but as a plausibly disease-modifying support for insulin secretory capacity, while I keep expectations realistic given the surrogate endpoints.
References
Piralaiy E, Rashidpour A, Ismael BR. Differential effects of aerobic, resistance, and combined trainings on first- and second-phase insulin secretion and glucose effectiveness in type 2 diabetes: a randomized controlled trial. J Diabetes Res. 2025;2025:9922344. doi:10.1155/jdr/9922344